Advaxis to hold End-of-Phase 2 meeting with FDA

The FDA agrees to an End-of-Phase 2 meeting with Advaxis (ADXS) to discuss the clinical results of its lead cancer immunotherapy candidate ADXS-HPV. The purpose of the meeting is to assess what needs to be done to move into a Phase 3 trial.

ADXS-HPV is being studied for the treatment of HPV-related cancers. The FDA designated it an Orphan Drug for Stage II-IV invasive cervical cancer.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs